Replies to post #4978 on Geron Corp (GERN)

[healthywelth]

I think You will ultimately WRONG , so that's where we differ. And now you said - Time will tell!

p.s. FDA FAST TRACK - FACT HISTORY SAID - 80% DRUG is APROVED !!!

Joseph Duato, Executive Vice President and Worldwide Chairman at JNJ, gave us a glimpse into how JNJ thinks regarding an acquisition of a drug like Imetelstat when he answered a question about the acquisition of Actelion.

“
Fundamentally, we looked at these elements of value creation for this acquisition: first, to what extent the new company would bring differentiated platforms or medicines; and to what extent would we be able to reach more patients, be competitive and achieve a stronger portfolio.

Although he was not speaking specifically about Imetelstat, I believe JNJ will use the same line of thinking when they approach a buyout of Geron. Hopefully, this provides some comfort to Geron investors who worry whether or not JNJ will proceed with a buyout. Last week, I analyzed the reasoning behind why I believe JNJ likes the results that Imetelstat has shown so far in clinical trials. Coupled with the reasoning I provided in this article regarding why a buyout makes sense, I believe the reward greatly outweighs the risk. If a buyout were to occur, I believe it could become a 10 bagger at today's prices.

[Charleston]

All signs point to an FDA approval. Perhaps an early approval. JNJ will buyout rather than payout. Continuation decision is a no brainer with its unprecedented survival stats.

[Charleston]

Actually, in that statement you are just repeating another FUD article trying to add momentum. Do not pretend to believe a lie to conceal your attempt to misdirect investors hoping it would mitigate your losses. 3 months from now, it will not be excusable to pretend the FUD article fooled everyone. It's only fooling fellow shorts themselves to short more. That short momentum fades quickly. Don't be the one caught holding the contract when it gaps up again